Welcome to Chiesi
Austria
Search results
You searched for:
Results: 77
1
Respiratory
Respiratory diseases are increasingly gaining in significance (allergies, environment-related asthma, smoking, etc.). For the Chiesi Group, the products for treating pulmonary diseases represent the most important point of focus in development and marketing. In particular, Chiesi has patented...
2
Neonatology
With its internally developed products Curosurf® and Peyona®, Chiesi offers two life-saving medicines that are used for premature babies.
Active ingredients
Caffeine citrate
Trade name: Peyona®
For interested parties from Austria: For more detailed information,...
3
Transplantmedicine
A transplantation becomes necessary if an organ is no longer able to fulfil all of its functions. Today, this treatment method is a well-established, successful procedure, such that most patients can once again lead an almost normal life after the organ transplant. After a transplantation,...
4
Other therapeutic fields
Active ingredients
Fosfomycin trometamol
Trade name: Monuril®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care)...
5
Rare Diseases
The European Union defines a disease as rare if not more than 5 in 10,000 people in the EU are affected by this disease. Worldwide, there are up to 8,000 “rare diseases”. In Austria, around 400,000 people suffer from a rare disease; throughout the EU, the number is an estimated...
6
Special Care
Active ingredients
Cangrelor
Trade name: Kengrexal®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
CDP-Cholin, Citicolin
Trade...
7
Home
-
8
The Company
Chiesi Pharmaceuticals in Austria
Chiesi Pharmaceuticals GmbH (formerly Torrex Chiesi Pharma GmbH) is a 100% subsidiary of the Italian family-owned company Chiesi Farmaceutici S.p.A. and is divided into three different business units.
The Chiesi Austria business unit is...
9
The History
The pioneering age
1935 - 1964
Chiesi was founded in 1935 in Parma, Italy, when Giacomo Chiesi, a chemist who dreamed of doing research, bought the Laboratorio Farmaceutico Parmense and embarked on his entrepreneurial adventure.
In the 1940s the Chiesi laboratory...
10
Therapeutical Areas
Therapy areas
11
Products
-
12
Transparency
Supply Chain Sustainability
The UN Global Compact defines Supply Chain sustainability as “the management of environmental, social, and economic impacts, and the encouragement of good governance practices throughout the lifecycles of goods and services”.
This definition...
13
Pharmacovigilance
Chiesi pharmaceuticals GmbH has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal...
14
Group Guidelines
The Code of Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.
The application of the following principles is guaranteed by the...
15
Ethics and Transparency
CODE OF CONDUCT
The Code of Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.
The application of the following principles is...
16
Transparency
-
17
Patient Service
Mehr Luft!
This website supports asthma and COPD patients by providing those affected and their relatives with information on disease symptoms, giving tips on how to cope in everyday life and discussing proper inhalation. Each week, we publish new blog entries on current topics.
Click...
18
Customer Service
Ordering of goods for Austria
A service for wholesalers and pharmacies.
The hours during which we accept orders are Mon-Thu 8:00-14:30 and Fri 8:00-12:00. Orders received after the end of the day will be processed on the following work day.
Tel. +43.1.407 39 19 –...
19
Medical Queries
Medical queries
Tel. +43.1.407 39 19 – 0 Fax +43.1.407 39 19 – 99018
Email medinfo.at@chiesi.com
Reporting adverse reactions/quality defects
Tel. +43.1.407 39 19 - 0 Fax +43.1.407...
20
Chiesi as an Employer
Build your career with us!
Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our...
21
Job Posting
You would like to apply?
Chiesi is continually looking for new talent for opportunities in all areas of the organization. Explore our global career portal and register to receive updates and current job openings.
Visit our global career portal here.Click here to access...
22
Awards
The Chiesi Group was awarded yesterday at the EURORDIS Black Pearl ceremony held in Brussels, with the Company Award for Innovation. The EURORDIS Black Pearl Award is an annual event held in Brussels to recognise the outstanding achievements and exceptional work of people making a difference...
23
Press Releases
Press Release, June 23rd, 2020: Annual & Sustainability Report 2020_ENGLISH
Press Release, March 27th, 2020: Chiesi acts in response to Covid-19 pandemic
Press Release, Feb. 6th, 2020: Chiesi Group Announces Establishment of New Global Rare Diseases Division
Press Release, Jan. 13th,...
24
Mission & Values
Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a...
25
Management Chiesi Austria
-
26
Contact
-
27
Sitemap
-
28
Data privacy
PRIVACY NOTICE
Under Article 13 of Regulation (EU) 2016/679 on the protection of individuals regarding the processing of personal data (hereinafter "GDPR")
This is a privacy notice provided by Chiesi Pharmaceuticals Gmbh ("Chiesi"), in accordance with the provisions of European Regulation No....
29
Cookie-Policy
Cookie Policy
This policy provides information regarding the use of cookies and other similar technologies on the website www.chiesi.at (hereinafter referred to as the "Website"). This notice is provided to the user in compliance with European legislation on the processing of personal data...
30
Imprint
Imprint acc. § 5 Abs 1 ECG
Name
Chiesi Pharmaceuticals GmbH (former Torrex Chiesi Pharma GmbH)
Managing Director
Dr....
31
Disclaimer
Contents of this website
The greatest possible care has been taken when preparing the contents of this website. We attempt to provide correct, complete, and up to date material. We do not accept any liability for foreign content, e.g., as a result of information expressly identified as being from...
32
Search result
-
33
AGB / AEB
Here you find our current AGB
Here you find our current AEB
34
Credits
This project was edited and produced by Dynamic Mind.
35
Contact
Chiesi Pharmaceuticals GmbH
Gonzagagasse 16/16
1010 Vienna, Austria
Tel. +43 / (0)1 / 407 39 19 – 0
Fax +43 / (0)1 / 407 39 19 – 99 999
Url www.chiesi.at
Email ...
36
Chiesi Foundation
Founded in 2005, the Chiesi Foundation Onlus is a no-profit organisation which seeks to capitalise on Chiesi’s legacy of knowledge in order to promote health and alleviate the suffering of patients affected by chronic obstructive respiratory diseases, rare diseases and neonatal diseases. The...
37
B-Corp Certification
Let’s make the world feel better.
As a B Corp in the biopharmaceutical industry, Chiesi is counted among businesses that are leading a global movement for an inclusive, equitable, and regenerative economy. It is an achievement to be proud of, and yet one that feels natural:...
38
Sustainability at Chiesi
Sustainability has always been a primary concern regarding the way Chiesi operates and today represents a crucial element of the strategic vision of the company, which is committed to:
promoting the professional and personal development of its people and their wellbeing;
protecting the planet...
39
Sustainability
-
40
Our approach
Sustainability has always been a primary concern in the way Chiesi operates and has increasingly become a focus with a view to shared value. Today, it represents a crucial element of the strategic vision of the company, which is committed to:
41
Global Value Chain
-
42
Environment
The concept of health has a much broader meaning at Chiesi and also encompasses that of the planet. This is also because the health of the planet and that of its inhabitants are interdependent. We therefore aim to act as a force for good and reduce the negative impacts on the areas where we...
43
Annual and Sustainability Report
-
44
Sustainability
-
45
Chiesi Foundation
Our commitment goes beyond the areas where we operate to improve the health and relieve the suffering of patients with respiratory and neonatal diseases in countries where the company does not commercialise its products and where access to quality healthcare is not always guaranteed. This is the...
46
We ACT - Sustainability Manifesto
We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make...
47
Sustainability Report
➡ Sustainability Report 2022
48
Sustainability of our supply chain
The 'United Nations Global Compact' defines supply chain sustainability as "the management of environmental, social and economic impacts and promotion of good governance practices throughout the entire life cycle of goods and services".
This definition underlines the importance of bringing the...
49
SpeakUp&BeHeard
-
50
Privacy-SpeakUp&BeHeard
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...
51
Chiesi Group calls for #ActionOverWords in the fight against climate change
-
52
Chiesi acts in response to Covid-19 pandemic
-
53
Chiesi Group Announces Establishment of New Global Rare Diseases Division
-
54
Chiesi Ankündigung umweltfreundliches Treibgas-Dosieraerosol
-
55
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox®
-
56
Annual & Sustainability Report 2020
-
57
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
-
58
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
-
59
Foster pMDI®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
60
Foster Nexthaler®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
61
Monuril®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
62
Prolastin®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
63
Trimbow®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
64
Bramitob®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
65
Cleviprex®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
66
Curosurf®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
67
Envarsus®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
68
Ferriprox®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
69
Raxone®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
70
Kengrexal®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
71
Peyona®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
72
Procysbi®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
73
Quinsair®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
74
Startonyl®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
75
Lamzede®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (EMA - European Medicines agency ) or consult your doctor or pharmacist.
76
Elfabrio®
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
77
-
For interested parties from Austria: For more detailed information, please refer to the published patient information leaflet (AGES Medicines & Medical Devices – Austrian Federal Office for Safety in Health Care) or consult your doctor or pharmacist.
© 2024 Chiesi Pharmaceuticals GmbH
Gonzagagasse 16/16 1010 Wien
Tel. +43.1.407 39 19 – 0
Fax +43.1.407 39 19 – 99019 oder 99999
Email: info.at@chiesi.com
Tel. +43.1.407 39 19 – 0
Fax +43.1.407 39 19 – 99019 oder 99999
Email: info.at@chiesi.com
CHIESI ON THE WEB
